Phase I/II study of decitabine/cedazuridine (ASXT727), venetoclax, and gilteritinib for patients with FLT3-mutated Acute Myeloid Leukemia or high-risk myelodysplastic syndrome
Year: 2025
Type: conference-abstract
Source: Blood
Authors: Roberta S. Azevedo, Nicholas Short, Alex Bataller, Naval Daver, Tapan Kadia, Courtney DiNardo, Alexandre Bazinet, Ghayas Issa, Elias Jabbour, Gautam Borthakur, Jayastu Senapati, Wei-Ying Jen, Kelly Chien, Steven Kornblau, Dono Tippett, Musa Yilmaz, Guillermo Montalban-Bravo, Hagop Kantarjian, Guillermo Garcia-Manero, Farhad Ravandi
Institution: The University of Texas MD Anderson Cancer Center
Language: English
Subfield: Hematology
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W4417015673